Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell transplantation for autoimmune diseases.

A Gratwohl1, J Passweg, I Gerber

  • 1Division of Haematology, Department of Internal Medicine, Kantonsspital Basel, Switzerland.

Best Practice & Research. Clinical Haematology
|April 2, 2002
PubMed
Summary

Autologous hematopoietic stem cell transplants (HSCTs) can induce remissions in severe autoimmune disorders but carry significant risks. Careful patient selection is crucial for successful outcomes in this evolving treatment area.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

Bone marrow transplantation·2016
Same author

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT.

Leukemia & lymphoma·2016

Area of Science:

  • Immunology
  • Rheumatology
  • Hematology

Background:

  • Haematopoietic stem cell transplants (HSCTs) offer potential for restoring immune function in severe autoimmune disorders.
  • Early research suggested intensive immunoablation followed by autologous HSCT could normalize immune reactivity.

Purpose of the Study:

  • To assess the efficacy and safety of autologous HSCT for severe autoimmune disorders based on phase I/II trial data.
  • To identify crucial factors for patient selection in HSCT for autoimmune diseases.

Main Methods:

  • International collaborative network collected phase I/II trial data from over 350 patients.
  • Analysis of remission rates, treatment-related mortality (TRM), and disease-specific outcomes.

Main Results:

Related Experiment Videos

  • Autologous HSCTs induce remissions across tested autoimmune disease categories, which can be transient or durable.
  • Treatment-related mortality (TRM) is approximately 10% at 1 year, influenced by conditioning intensity and disease stage.
  • Significant interdisease differences in outcomes exist; patient selection is critical, excluding those with advanced or irreversible organ damage.

Conclusions:

  • Autologous HSCT is a viable option for severe autoimmune disorders, but carries substantial risks.
  • Further prospective randomized trials are necessary to compare HSCT efficacy against standard therapies for specific conditions like systemic sclerosis, multiple sclerosis, and rheumatoid arthritis.